Accelerating Europe's Progress in CNS Gene Therapy
Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic
With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.
As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.
View the world-class speaker faculty and topics for discussion here
Your 2022 Expert Speakers Included:
Fatima Bosch
Professor & Director, Center of Animal Biotechnology & Gene Therapy
Universitat Autònoma de Barcelona, Spain
Stéphane Palfi
Chef de Service de Neurochirurgie, Directeur Equipe de recherche, Hôpital Henri Mondor
Université Paris-Est Créteil (UPEC)
2022 Partners Included:
Other Events In The Gene Therapy Series:
